drugset / Trial / NCT01331915
Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients
Phase 1/2
Unknown
23 enrolled
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Institut Pasteur · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
In this phase I study, the investigators want to vaccine with THERAVAC® (an inactivated toxin coupled to melanoma antigen) some patients with advanced metastatic melanoma disease. The primary objective is to analyze the safety of the inreasing doses of vaccine. The secondary objective is to document whether this vaccine can induce tumor regression in immunized patients.
Timeline
- Start
- 2010-09
- Primary completion
- 2013-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Theravac | Vaccine | 50 ug | Other |
| Subject | Theravac | Vaccine | 150 ug | Other |
| Subject | Theravac | Vaccine | 250 ug | Other |